stockrow
Saturday 31 October 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.
186.38
11.98
+6.87%
Follow AZN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.64 | 26.58 | 29.38 | 28.13 |
P/S ratio |
3.99 | 4.63 | 5.05 | 4.79 | |
P/FCF ratio |
23.93 | 30.83 | 38.48 | 46.94 | |
P/Operating CF |
45.16 | 116.08 | 90.95 | 102.65 | |
P/B ratio |
5.04 | 5.58 | 6.45 | 5.84 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.38 | 5.00 | 5.46 | 5.19 | |
EV/EBITDA |
13.15 | 15.09 | 16.38 | 15.67 | |
EV/Operating CF |
16.81 | 20.16 | 23.19 | 23.25 | |
EV/FCF |
26.27 | 33.32 | 41.54 | 50.85 | |
Quick Ratio |
0.69 | 0.72 | 0.70 | 0.67 | |
Current Ratio |
0.88 | 0.94 | 0.91 | 0.89 | |
Net Debt/EBITDA |
4.42 | 4.90 | 4.33 | 4.80 | |
Debt/Assets |
26.97% | 24.39% | 28.09% | 25.46% | |
Debt/Equity |
0.67 | 0.57 | 0.68 | 0.59 | |
Asset Turnover |
0.53 | 0.54 | 0.55 | 0.54 | |
Operating CF/Net income |
2.03 | 1.01 | 1.09 | 1.14 | |
Capex/Depreciation |
(1.11) | (0.82) | (1.09) | (1.55) | |
Interest Coverage |
8.26 | 6.31 | 10.80 | 7.27 | |
Research and Development Expense of Revenue |
24.11% | 24.91% | 22.84% | 26.35% | |
Selling, General and Administrative Expense of Revenue |
34.45% | 36.41% | 33.10% | 37.68% | |
Intangible Assets out of Total Assets |
0.52 | 0.52 | 0.51 | 0.51 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.17) | (0.13) | (0.12) | (0.13) | |
Graham Number |
63.61 | 68.35 | 67.97 | 70.19 | |
Earnings Yield |
4.06% | 3.76% | 3.40% | 3.56% | |
Free Cash Flow Yield |
4.18% | 3.24% | 2.60% | 2.13% | |
Revenue per Share |
9.79 | 10.01 | 9.87 | 9.92 | |
Operating CF per Share |
3.31 | 1.51 | 2.17 | 1.85 | |
Capex per Share |
(1.11) | (0.80) | (0.96) | (1.92) | |
Free Cash Flow per Share |
2.20 | 0.71 | 1.21 | (0.07) | |
Cash per Share |
5.28 | 3.76 | 4.97 | 3.25 | |
Shareholders Equity per Share |
29.64 | 31.45 | 30.59 | 32.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.64 | 31.45 | 30.59 | 32.48 | |
Free Cash Flow |
3,409.00 | 1,098.00 | 1,874.00 | (116.00) | |
Working Capital |
(4,114.00) | (1,894.00) | (2,957.00) | (3,588.00) | |
Capital Expenditures |
(1,725.00) | (1,244.00) | (1,485.00) | (2,981.00) | |
Net Current Asset Value |
(38,545.00) | (36,632.00) | (37,018.00) | (37,498.00) | |
EV/EBIT |
19.89 | 21.38 | 23.04 | 22.80 | |
Capex to Sales |
0.11 | 0.08 | 0.10 | 0.19 | |
Price to Operating Income |
18.11 | 19.78 | 21.34 | 21.05 | |
| Other line items | |||||
Average Receivables |
14,350.00 | 15,583.00 | 14,990.00 | 15,579.00 | |
Average Payables |
23,356.00 | 23,872.50 | 22,524.50 | 23,439.50 | |
Average Inventory |
6,127.50 | 5,922.50 | 6,227.00 | 6,699.50 | |
Average Assets |
109,689.00 | 109,054.50 | 110,134.00 | 114,127.50 | |
Average Common Equity |
43,388.00 | 44,795.00 | 44,257.50 | 47,590.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026